Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311376 | 0.80 | GPR35 (0.46) | GPR35KDM4EALDH1A1HPGDGPR17 | |
| SCHEMBL1311620 | 0.79 | EIF4A3 (0.42) | GPR35KDM4EALDH1A1HPGDGPR17 | |
| SCHEMBL1311895 | 0.71 | MAP2 (0.33) | MAP2GPR35KDM4EALDH1A1HPGD | |
| SCHEMBL1613575 | 0.67 | KDM4E (0.61) | MAP2KDM4EALDH1A1HPGD | |
| SCHEMBL31416400 | 0.66 | GPR17 (0.48) | MAP2GPR17 | |
| SCHEMBL31332450 | 0.64 | GPR17 (0.61) | KDM4EALDH1A1HPGDGPR17 | |
| SCHEMBL1244081 | 0.64 | DAO (0.42) | MAP2GPR35KDM4EALDH1A1HPGD | |
| SCHEMBL9038402 | 0.64 | GPR17 (0.61) | KDM4EALDH1A1HPGDGPR17 | |
| SCHEMBL8910112 | 0.64 | GPR17 (0.61) | MAP2KDM4EHPGDGPR17 | |
| SCHEMBL6921821 | 0.64 | MAP2 (0.65) | MAP2KDM4EALDH1A1GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | MAP2 352/4885GPR35 1199/4885KDM4E 3091/4885 |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | MAP2 352/4885GPR35 1199/4885KDM4E 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.